litlas
ログインアカウント作成

Jan A. Burger

1999–2025 年に発表

189
論文数
33,707
被引用数
102
h 指数
185
i10 指数

被引用数

Jan A. Burger の年別被引用数1992 年: 被引用 2 件2000 年: 被引用 8 件2001 年: 被引用 29 件2002 年: 被引用 45 件2003 年: 被引用 60 件2004 年: 被引用 52 件2005 年: 被引用 70 件2006 年: 被引用 78 件2007 年: 被引用 114 件2008 年: 被引用 135 件2009 年: 被引用 168 件2010 年: 被引用 173 件2011 年: 被引用 183 件2012 年: 被引用 223 件2013 年: 被引用 326 件2014 年: 被引用 301 件2015 年: 被引用 470 件2016 年: 被引用 369 件2017 年: 被引用 391 件2018 年: 被引用 402 件2019 年: 被引用 1,376 件2020 年: 被引用 1,594 件2021 年: 被引用 1,620 件2022 年: 被引用 1,011 件2023 年: 被引用 723 件2024 年: 被引用 1,121 件2025 年: 被引用 454 件2026 年: 被引用 16 件1993〜1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,018 件、この内訳の 27.9%中国: 引用元論文 951 件、この内訳の 8.8%ドイツ: 引用元論文 788 件、この内訳の 7.3%イタリア: 引用元論文 728 件、この内訳の 6.7%イギリス: 引用元論文 692 件、この内訳の 6.4%フランス: 引用元論文 443 件、この内訳の 4.1%スペイン: 引用元論文 335 件、この内訳の 3.1%オーストラリア: 引用元論文 332 件、この内訳の 3.1%カナダ: 引用元論文 279 件、この内訳の 2.6%オランダ: 引用元論文 258 件、この内訳の 2.4%スイス: 引用元論文 225 件、この内訳の 2.1%日本: 引用元論文 221 件、この内訳の 2%
0%27.9%その他 23.5%

機関

分野

  • Medicine75.8%
  • Biochemistry, Genetics and Molecular Biology14.6%
  • Immunology and Microbiology6.6%
  • Chemistry0.7%
  • Computer Science0.4%
  • Neuroscience0.4%
  • その他1.5%

トピック

  • Chronic Lymphocytic Leukemia Research12.3%
  • Lymphoma Diagnosis and Treatment7.6%
  • Chronic Myeloid Leukemia Treatments4.7%
  • Acute Myeloid Leukemia Research4.2%
  • Immunodeficiency and Autoimmune Disorders3.1%
  • Chemokine receptors and signaling3.1%
  • その他65%

共著者

全論文

検索で開く
  1. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    著者: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 被引用: 1,562

  2. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    著者: Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia - Blood Advances 2022 被引用: 269

  3. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 被引用: 2,249

  4. Targeting B cell receptor signalling in cancer: preclinical and clinical advances

    著者: Jan A. Burger, Adrian Wiestner - Nature reviews. Cancer 2018 被引用: 422

  5. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    著者: Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach - American Journal of Hematology 2019 被引用: 473

  6. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

    著者: Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver, Tapan M. Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Ghayas C. Issa, Guillermo Montalban‐Bravo, Nicholas J. Short, Musa Yılmaz, Prithviraj Bose, Elias Jabbour, Koichi Takahashi, Jan A. Burger, Guillermo Garcia‐Manero, Nitin Jain, Steven M. Kornblau, Philip A. Thompson, Zeev Estrov, Lucia Masárová, Koji Sasaki, Srđan Verstovšek, Alessandra Ferrajoli, William Weirda, Sa A. Wang, Sergej Konoplev, Zhining Chen, Sherry Pierce, Jing Ning, Wei Qiao, Farhad Ravandi, Michael Andreeff, John S. Welch, Hagop M. Kantarjian, Marina Konopleva - The Lancet Haematology 2020 被引用: 331

  7. Ibrutinib and Venetoclax for First-Line Treatment of CLL

    著者: Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Nathan Fowler, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yılmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Koji Sasaki, Rashmi Kanagal‐Shamanna, Keyur P. Patel, Jeffrey L. Jorgensen, Naveen Garg, Xuemei Wang, Katrina Sondermann, Nichole Cruz, Chongjuan Wei, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda - New England Journal of Medicine 2019 被引用: 504

  8. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    著者: Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps - Leukemia 2019 被引用: 463

  9. Bruton Tyrosine Kinase Inhibitors

    著者: Jan A. Burger - The Cancer Journal 2019 被引用: 193

  10. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia

    著者: Wan Zhang, Dunyaporn Trachootham, Jinyun Liu, Gang Chen, Hélène Pelicano, Celia Garcı́a-Prieto, Weiqin Lu, Jan A. Burger, Carlo M. Croce, William Plunkett, Michael J. Keating, Peng Huang - Nature Cell Biology 2012 被引用: 353

  11. Molecular map of chronic lymphocytic leukemia and its impact on outcome

    著者: Binyamin A. Knisbacher, Ziao Lin, Cynthia K. Hahn, Ferran Nadeu, Martí Duran‐Ferrer, Kristen E. Stevenson, Eugen Tausch, Julio Delgado, Alex Barbera-Mourelle, Amaro Taylor‐Weiner, Pablo Bousquets‐Muñoz, Ander Díaz‐Navarro, Andrew Dunford, Shankara Anand, Helene Kretzmer, Jesús Gutiérrez‐Abril, Sara López-Tamargo, Stacey M. Fernandes, Clare Sun, Mariela Sivina, Laura Z. Rassenti, Christof Schneider, Shuqiang Li, Laxmi Parida, Alexander Meissner, François Aguet, Jan A. Burger, Adrian Wiestner, Thomas J. Kipps, Jennifer R. Brown, Michael Hallek, Chip Stewart, Donna Neuberg, José I. Martín‐Subero, Xosé S. Puente, Stephan Stilgenbauer, Catherine J. Wu, Elı́as Campo, Gad Getz - Nature Genetics 2022 被引用: 148

  12. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment

    著者: Jan A. Burger, Thomas J. Kipps - Blood 2005 被引用: 1,165

  13. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

    著者: Constantine S. Tam, Judith Trotman, Stephen Opat, Jan A. Burger, Gavin Cull, David Gottlieb, Rosemary Harrup, Patrick B. Johnston, Paula Marlton, Javier Muñoz, John F. Seymour, David Simpson, Alessandra Tedeschi, Rebecca Elstrom, Yiling Yu, Zhiyu Tang, Lynn Han, Jane Huang, William Novotny, Lai Wang, Andrew W. Roberts - Blood 2019 被引用: 367

  14. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

    著者: Nitin Jain, Michael J. Keating, Philip A. Thompson, Alessandra Ferrajoli, Jan A. Burger, Gautam Borthakur, Koichi Takahashi, Zeev Estrov, Koji Sasaki, Nathan Fowler, Tapan M. Kadia, Marina Konopleva, Yesid Alvarado, Musa Yılmaz, Courtney D. DiNardo, Prithviraj Bose, Maro Ohanian, Naveen Pemmaraju, Elias Jabbour, Rashmi Kanagal‐Shamanna, Keyur Patel, Wei Wang, Jeffrey L. Jorgensen, Sa A. Wang, Naveen Garg, Xuemei Wang, Chongjuan Wei, Nichole Cruz, Ana Ayala, William Plunkett, Hagop M. Kantarjian, Varsha Gandhi, William G. Wierda - JAMA Oncology 2021 被引用: 112

  15. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien - Clinical Cancer Research 2020 被引用: 183

  16. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

    著者: Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutré, Marie‐Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael M. Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger - Haematologica 2017 被引用: 258

  17. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

    著者: Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Xuelin Huang, Nitin Jain, Koji Sasaki, Naval Daver, Naveen Pemmaraju, Joseph D. Khoury, Jeffrey L. Jorgensen, Yesid Alvarado, Marina Konopleva, Guillermo Garcia‐Manero, Tapan M. Kadia, Musa Yılmaz, Gautam Bortakhur, Jan A. Burger, Steven M. Kornblau, William G. Wierda, Courtney D. DiNardo, Alessandra Ferrajoli, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Elias Jabbour - The Lancet Oncology 2018 被引用: 241

  18. B cell receptor signaling in chronic lymphocytic leukemia

    著者: Jan A. Burger, Nicholas Chiorazzi - Trends in Immunology 2013 被引用: 355

  19. Treatment of Chronic Lymphocytic Leukemia

    著者: Jan A. Burger - New England Journal of Medicine 2020 被引用: 235

  20. Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

    著者: Farhad Ravandi, Susan O’Brien, Jörge E. Cortes, Deborah Thomas, Rebecca Garris, Stefan Faderl, Jan A. Burger, Michael Rytting, Alessandra Ferrajoli, William G. Wierda, Srđan Verstovšek, Richard E. Champlin, Partow Kebriaei, Deborah McCue, Xuelin Huang, Elias Jabbour, Guillermo Garcia‐Manero, Zeev Estrov, Hagop M. Kantarjian - Cancer 2015 被引用: 223

  21. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

    著者: Ian W. Flinn, Susan O’Brien, Brad S. Kahl, Manish R. Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey A. Jones, Jan A. Burger, Nitin Jain, Virginia Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven M. Horwitz - Blood 2017 被引用: 253

  22. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

    著者: Julia Hoellenriegel, Dirk Zboralski, Christian Maasch, Nathalie Y. Rosin, William G. Wierda, Michael J. Keating, Anna Kruschinski, Jan A. Burger - Blood 2013 被引用: 236

  23. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

    著者: Jan A. Burger, Dan A. Landau, Amaro Taylor‐Weiner, Ivana Božić, Huidan Zhang, Kristopher A. Sarosiek, Lili Wang, Chip Stewart, Jean Fan, Julia Hoellenriegel, Mariela Sivina, Adrian M. Dubuc, Cameron Fraser, Yulong Han, Shuqiang Li, Kenneth J. Livak, Lihua Zou, Youzhong Wan, Sergej Konoplev, Carrie Sougnez, Jennifer R. Brown, Lynne V. Abruzzo, Scott L. Carter, Michael J. Keating, Matthew S. Davids, William G. Wierda, Kristian Cibulskis, Thorsten Zenz, Lillian Werner, Paola Dal Cin, Peter Kharchencko, Donna Neuberg, Hagop M. Kantarjian, Eric S. Lander, Stacey Gabriel, Susan O’Brien, Anthony Letai, David A. Weitz, Martin A. Nowak, Gad Getz, Catherine J. Wu - Nature Communications 2016 被引用: 346

  24. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    著者: John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien - Blood 2015 被引用: 656